Pharma Stocks
-
Assessing Daiichi Sankyo Company (TSE:4568) Valuation After New Lipodia Digital Health Partnership
Daiichi Sankyo Company (TSE:4568) has moved further into digital health by announcing an exclusive partnership with GAIA to commercialise Lipodia,…
Read More » -
Strides Pharma Science Ltd Shows Technical Momentum Shift…
Technical Momentum and Indicator Overview Strides Pharma Science Ltd (NSE: 688428) closed at ₹853.20 on 6 Mar 2026, marking a…
Read More » -
2 Top Healthcare Dividend Stocks to Buy and Hold Forever
Key Points Bristol Myers Squibb can navigate the dreaded patent cliff while maintaining modest dividend growth. Medtronic’s strong, innovative business…
Read More » -
Seven Nifty 500 stocks fall up to 47% in three months; do you own any?
The market correction caused by the India-US tariff issue, subdued quarterly earnings and the ongoing war between US-Israel and Iran…
Read More » -
Sun Pharmaceutical Sees Surge in Call Option Activity Ahe…
Robust Call Option Activity Highlights Bullish Positioning The most active call options for Sun Pharmaceutical Industries Ltd are concentrated at…
Read More » -
Ligand Pharmaceuticals (LGND) Is Up 8.1% After Swinging to Profit and Filing New Equity Shelf – What’s Changed
In late February 2026, Ligand Pharmaceuticals reported a sharp improvement in fourth-quarter and full-year 2025 results, turning prior-year losses into…
Read More » -
A Look At Royalty Pharma (RPRX) Valuation After Robust 2025 Results And Expansion Plans In Asia
Royalty Pharma (RPRX) has been in focus after reporting 2025 financial results that included 16% growth in total portfolio receipts,…
Read More » -
Sanofi Rumored Bid And Regulatory Shifts Reframe Ocular Therapeutix Valuation
Rumors are circulating that Sanofi is considering a significantly higher acquisition bid for Ocular Therapeutix (NasdaqGM:OCUL). The speculation follows recent…
Read More » -
Gland Pharma Ltd Technical Momentum Shifts Amid Mixed Mar…
Current Price and Market Context As of 4 March 2026, Gland Pharma’s stock closed at ₹1,790.30, down 1.79% from the…
Read More » -
Royalty Pharma plc (RPRX) Earns $51 Target as 2026 Growth Outlook Exceeds Expectations
Royalty Pharma plc (NASDAQ:RPRX) is among the 11 Best Low Priced Growth Stocks to Buy Right Now. Royalty Pharma plc…
Read More »